The cell cycle arrest biomarkers TIMP2•IGBP7 (NephroCheck, Biomerieux, Inc) have been used to direct clinical bundles to optimize hemodynamics and limit nephrotoxic medication exposure and have led to decreased AKI development rates and severity in adults after cardiac surgery27 and noncardiac surgery.28 The gene discussed is TIMP2; the disease is acute kidney injury.